CG Oncology Revenue

In the year 2025, CG Oncology had annual revenue of $4.04M with 254.70% growth. CG Oncology had revenue of $2.32M in the quarter ending December 31, 2025, with 409.21% growth.

Revenue (ttm)

$4.04M

Revenue Growth

+254.70%

P/S Ratio

1,293.28

Revenue / Employee

$28,451

Employees

142

Market Cap

5.23B

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	4.04M	2.90M	254.70%
Dec 31, 2024	1.14M	935.00K	458.33%
Dec 31, 2023	204.00K	13.00K	6.81%
Dec 31, 2022	191.00K	-10.17M	-98.16%
Dec 31, 2021	10.36M	-	-

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
PTC Therapeutics	1.73B
Caris Life Sciences	812.03M
Mirum Pharmaceuticals	521.31M
Protagonist Therapeutics	46.02M
CRISPR Therapeutics AG	3.51M

Revenue Rankings

CGON News

10 days ago - CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates - GlobeNewsWire
14 days ago - CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
7 weeks ago - CG Oncology, Inc. (CGON) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
2 months ago - CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene - Seeking Alpha
2 months ago - CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC - GlobeNewsWire
2 months ago - CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
2 months ago - CG Oncology Undervalued Going Into A Busy 2026 - Seeking Alpha
3 months ago - New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer - GlobeNewsWire

More News